Illuminare-1
Nerve visualization in radical prostatectomy (and other surgeries)
Phase 1Active
Key Facts
Indication
Nerve visualization in radical prostatectomy (and other surgeries)
Phase
Phase 1
Status
Active
Company
About Illuminare Biotechnologies
Illuminare Biotechnologies is pioneering a novel surgical aid focused on preventing iatrogenic nerve injury through real-time visualization. Its lead asset, Illuminare-1, has shown promising safety and initial efficacy in a Phase 1 trial at Memorial Sloan Kettering, with results published in JAMA Surgery. The company is a private, pre-revenue entity planning to advance into Phase 2 clinical development in 2026, targeting significant unmet needs in oncologic and other complex surgeries.
View full company profile